Interpace Biosciences, Inc. has announced preliminary, unaudited revenue figures for the third quarter of 2026. According to a press release filed with the SEC on October 14, 2026, the company expects revenue for the three months ended September 30, 2026, to fall within a range of $10.1 million to $10.4 million.
The company reported that this projected revenue represents an increase of approximately 11% to 14% when compared to the second quarter of 2026. Specifically, revenue for Q2 2026 was reported at $9.1 million. Additionally, the company noted an expected year-over-year increase of approximately 15% to 18% compared to the third quarter of 2025, which saw revenue of $8.8 million.
The company cautions that these figures are preliminary and unaudited. They are based on information currently available to management and remain subject to the completion of quarter-end closing procedures and review by the company's independent registered public accounting firm. Actual results may differ materially from the range presented in the announcement.
